Drugs › CD52-directed cytolytic antibody
Brand name · Alemtuzumab
Campath: adverse event reports filed with FDA
2,751 reports list it as a suspect or interacting product, 2004–2026. Class: CD52-directed cytolytic antibody. Also reported as Campath 30.
- 2,751
- reports as suspect product
- 0% of all reports · about 122 a year
- 38
- reports, 12 months to June 2026
- 32 in the 12 months before
- 91.5%
- marked serious by the reporter
- 86% across the class
- 34.4%
- record death among outcomes, as reported
- 945 reports · not verified by FDA
Between January 2004 and June 2026, 2,751 adverse event reports received by FDA list the brand name Campath (alemtuzumab) as a suspect or interacting product. Reports that mention it only as a concomitant medication (345) are left out of every figure here.
In the 12 months to June 2026, 38 reports listed it, up 19% from 32 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 122 reports a year and 0% of the 20,646,523 reports in the database, and 15.9% of the reports for the CD52-directed cytolytic antibody class. How many people take it is not in the data, so a count is not a rate of occurrence.
The MedDRA terms listed most often are pyrexia (9.1%), cytomegalovirus infection (7.4%) and death (7.3%). A report can list several reactions, so shares add to more than 100%; 687 different terms appear across these reports. Pyrexia is recorded in 9.1% of these reports, about the same share as in the median CD52-directed cytolytic antibody drug (9.1%).
91.5% of the reports are marked serious by the reporter (86% across the class); 34.4% record death among the outcomes and 36% record hospitalisation, as reported. 42.9% of the reports came from physicians, and the largest patient age group is 45 to 64 (23%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Campath reports recording the termmedian drug in cd52-directed cytolytic antibody
- Pyrexiafever9.1%251
- Cytomegalovirus infection7.4%203
- Deaththe patient died; cause not stated by this term7.3%200
- Off label useused for a purpose or in a way not on the label6.7%185
- Pneumonialung infection4.2%115
- Neutropenialow neutrophils, a type of white blood cell4.1%112
- Pancytopenialow counts of all blood cells3.7%101
- Hypotensionlow blood pressure3.3%91
- Thrombocytopenialow platelets3.2%89
- Febrile neutropeniafever with low white blood cells3.2%88
- Sepsisa severe body-wide response to infection3.1%86
- Drug ineffectivethe medicine did not work as expected2.8%78
- Chillschills or shivering2.8%76
- Diarrhoealoose or frequent stools2.7%73
- Dyspnoeashortness of breath2.6%72
- Disease progressionthe disease advanced2.6%71
- Respiratory failurethe lungs could not supply enough oxygen2.5%69
- Infectionan infection, type not specified2.4%67
- Platelet count decreasedlow platelet count2.4%67
- Multi-organ failure2.3%63
- Anaemialow red blood cells2.1%59
- Renal failurekidney failure2.1%59
- Nauseafeeling sick2%56
- Astheniaweakness or lack of energy2%54
- General physical health deteriorationgeneral decline in health1.9%52
- Haemoglobin decreasedlow haemoglobin1.8%50
- Transplant rejection1.8%49
- Fatiguetiredness1.7%48
- Pleural effusionfluid around the lung1.7%47
Top 30 of 687 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 3 drugs in the cd52-directed cytolytic antibody class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 17,330 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 49.4% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Chronic lymphocytic leukaemia | 577 | 21% |
| Bone marrow conditioning regimen | 169 | 6.1% |
| Stem cell transplant | 154 | 5.6% |
| Multiple sclerosis | 98 | 3.6% |
| T-cell prolymphocytic leukaemia | 69 | 2.5% |
| Renal transplant | 40 | 1.5% |
The indication field is filled in by the reporter and is often blank; shares are of all 2,751 reports.
In context
| Measure | Campath | CD52-directed cytolytic antibody | All reports |
|---|---|---|---|
| Reports as suspect product | 2,751 | 17,330 | 20,646,523 |
| Share of that pool | — | 15.9% | 0% |
| Reports, latest 12 months | 38 | — | 1,332,454 |
| Marked serious | 91.5% | 86% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 344 | 143 | 91 |
| Hospitalisation recorded, per 1,000 reports | 360 | 326 | 213 |
| Consumer-filed share | 10.4% | 22.1% | 45.8% |
| Top term, share of reports | Pyrexia 9.1% | median 9.1% | 1.6% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the cd52-directed cytolytic antibody class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Alemtuzumab | generic | 8,610 | 426 | 95.8% |
| Lemtrada | brand | 5,969 | 49 | 69.4% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Campath reports
How many adverse event reports has FDA received for Campath?
2,751 reports list Campath as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 38 of them arrived in the latest 12 months. Another 345 list it only as a concomitant medication.
What reactions are recorded in Campath reports?
pyrexia (9.1%), cytomegalovirus infection (7.4%), death (7.3%), off label use (6.7%) and pneumonia (4.2%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Campath was responsible.
How serious are the reports?
91.5% are marked serious by the reporter. Among the outcomes recorded, 34.4% of reports include death and 36% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
physician (42.9%), other health professional (32%) and consumer or non-health professional (10.4%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Campath rising?
38 reports in the 12 months to June 2026, up 19% from 32 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Campath was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Campath?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Campath as a suspect or interacting product; reports listing it only as a concomitant medication (345) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.